Rationale for Adding BDC-1001 to Immune Checkpoint Inhibitor Therapy in HER2+ Breast Cancer

Ecaterina Ileana Dumbrava, MD, discusses the rationale for combing BDC-1001, a HER2-targeting TLR7/8 immune-stimulating antibody conjugate with an immune checkpoint inhibitor.

Ecaterina Ileana Dumbrava, MD, an assistant professor in the Department of Investigational Cancer Therapeutics, of the Division of Cancer Medicine, at the University of Texas MD Anderson Cancer Center, discusses the rationale for combing BDC-1001, a HER2-targeting TLR7/8 immune-stimulating antibody conjugate with an immune checkpoint inhibitor.

BDC-1001 is currently being studied in an ongoing phase 1 study to determine, safety, durability and proper dosage. According to Dumbrava, synergistic activity was seen between the 2 agents in preclinical models. These preclinical model also had anti-PB1 activity and immunologic memory.

It was hypothesized that the activity observed preclinically may translate in human subjects. Researchers hope that the combination will lead to a durable and sustained responses.